C-ZHU2regenerative medicine, stem cell therapies, veterinary therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a ready-to-use regenerative therapy for canine atopic dermatitis.
Stem cell therapy for veterinary regenerative medicine; specific protocol not disclosed in supplied material.
Listed by Gallant as a therapy in development following the FDA structured review and approval process.
Develop a ready-to-use regenerative therapy for canine osteoarthritis.
Stem cell therapy for veterinary regenerative medicine; specific protocol not disclosed in supplied material.
Listed by Gallant as a therapy in development following the FDA structured review and approval process.
Provide nationwide stem cell banking for dogs.
Consumer stem cell banking service; operational details not disclosed in supplied material.
A public record title states that Gallant launched stem cell banking for dogs nationwide.
Treat refractory feline chronic gingivostomatitis by reducing inflammation, supporting tissue recovery, and improving quality of life in cats.
Intravenous allogeneic uterine-derived mesenchymal stromal cell therapy; study used two 20-million-cell doses 14 days apart in client-owned cats.
Long-term field safety extension followed 35 cats through day 365 and reported 1-year safety and effectiveness outcomes.
No serious adverse events were associated with UMSC administration. At 1 year, owner-reported improvement was 65.6%, veterinarian-assessed oral lesion improvement was 46.9%, mean lesion score reduction was 33%, and 22% of cats achieved clinical cure.
Develop a ready-to-use regenerative therapy for feline chronic kidney disease.
Stem cell therapy for veterinary regenerative medicine; specific protocol not disclosed in supplied material.
Listed by Gallant as a therapy in development following the FDA structured review and approval process.
Develop a ready-to-use regenerative therapy for feline osteoarthritis.
Stem cell therapy for veterinary regenerative medicine; specific protocol not disclosed in supplied material.
Listed by Gallant as a therapy in development following the FDA structured review and approval process.
Create off-the-shelf regenerative stem cell therapies for veterinary diseases that target disease at its source, reduce inflammation, restore tissue function, and support long-term recovery in pets.
Allogeneic stem cell therapy platform for veterinary medicine; supplied material specifically identifies uterine-derived mesenchymal stromal cells in the FCGS study.
Multiple therapies are listed in development under Gallant's product pipeline and FDA structured review process.